Connor Clark & Lunn Investment Management Ltd. Purchases Shares of 518,460 Oric Pharmaceuticals, Inc. $ORIC

Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) during the second quarter, HoldingsChannel reports. The institutional investor purchased 518,460 shares of the company’s stock, valued at approximately $5,615,000.

Several other institutional investors and hedge funds also recently modified their holdings of ORIC. Defilade Capital Management L.P. acquired a new position in Oric Pharmaceuticals during the 1st quarter worth approximately $10,680,000. Siren L.L.C. grew its stake in shares of Oric Pharmaceuticals by 197.6% during the 1st quarter. Siren L.L.C. now owns 2,998,192 shares of the company’s stock worth $37,987,000 after acquiring an additional 1,990,617 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Oric Pharmaceuticals by 19.9% in the first quarter. Dimensional Fund Advisors LP now owns 1,471,290 shares of the company’s stock valued at $18,637,000 after purchasing an additional 244,060 shares during the last quarter. Blue Owl Capital Holdings LP acquired a new stake in shares of Oric Pharmaceuticals in the second quarter valued at approximately $4,332,000. Finally, UBS Group AG lifted its position in shares of Oric Pharmaceuticals by 116.6% in the fourth quarter. UBS Group AG now owns 734,858 shares of the company’s stock worth $6,011,000 after purchasing an additional 395,622 shares in the last quarter. 95.05% of the stock is owned by institutional investors and hedge funds.

Oric Pharmaceuticals Trading Down 1.2%

NASDAQ:ORIC opened at $13.74 on Friday. Oric Pharmaceuticals, Inc. has a 1-year low of $7.23 and a 1-year high of $14.93. The firm has a fifty day simple moving average of $11.76 and a 200 day simple moving average of $10.71. The stock has a market capitalization of $1.42 billion, a PE ratio of -10.18 and a beta of 1.02.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.02). On average, equities analysts predict that Oric Pharmaceuticals, Inc. will post -1.53 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on ORIC. Citigroup reduced their target price on shares of Oric Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating for the company in a report on Tuesday, May 5th. Wall Street Zen upgraded shares of Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 25th. HC Wainwright raised their price objective on Oric Pharmaceuticals from $25.00 to $27.00 and gave the company a “buy” rating in a report on Monday, August 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Oric Pharmaceuticals in a research report on Friday, May 22nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Friday, July 17th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Oric Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.45.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.